Zenas BioPharma, Inc.
- Stock
- Ticker ZBIO
- Nasdaq
Performance, volatility and drawdowns of Zenas BioPharma, Inc. since 09/2024, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.
Performance
$10,000 grew to $7,632. Global equities (VT): $10,273.
Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.
Declines from the peak
Lowest point −75.0% in 01/2025, measured from the peak in 10/2024. It took 12 months to get back to the old peak.
Financial statements
Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures
| Quarter end | 12/2024 | 03/2025 | 06/2025 | 09/2025 | 12/2025 | 03/2026 | 06/2026 | 09/2026 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 5.0 | 10 | 0.0 | 0.0 | 0.0 | – | 1.0 | 10 |
| Operating income | -56 | -37 | -55 | -53 | -238 | -77 | -108 | -103 |
| EBITDA | -56 | -37 | -55 | -53 | -238 | -77 | -108 | -103 |
| Net income | -53 | -34 | -52 | -51 | -240 | -81 | -111 | -109 |
| Earnings per share | 16.94 | -0.80 | -1.25 | -1.22 | -5.17 | -1.46 | -1.77 | -1.65 |
| Balance sheet | ||||||||
| Total assets | 370 | 334 | 293 | 322 | 384 | 748 | 702 | 675 |
| Liabilities | 58 | 49 | 53 | 126 | 141 | 412 | 455 | 463 |
| Equity | 312 | 284 | 240 | 196 | 242 | 336 | 247 | 212 |
| Cash | 320 | 197 | 44 | 116 | 111 | 500 | 197 | 178 |
| Long-term debt | – | – | – | 73 | 79 | – | – | – |
| Cash flow | ||||||||
| Operating cash flow | -39 | -37 | -42 | -41 | -52 | -75 | -57 | -58 |
| Capital expenditure | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Free cash flow | -39 | -37 | -42 | -41 | -52 | -75 | -57 | -58 |
Value it:DCF calculatorMultiples calculator
Annual returns
* partial year.
Quarterly reports
Filing date with the SEC and earnings per share of the quarter
| Day | Earnings per share |
|---|---|
| 5 Nov 2026 | −$1.65 |
| 13 Aug 2026 | −$1.77 |
| 13 May 2026 | −$1.46 |
| 16 Mar 2026 | −$5.17 |
| 12 Nov 2025 | −$1.22 |
| 12 Aug 2025 | −$1.25 |
| 15 May 2025 | −$0.80 |
| 11 Mar 2025 | $16.94 |
| 12 Nov 2024 | $1.96 |
Key metrics
Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.
Valuation
- Market cap
- €1.5bn
- Market cap in trading currency
- $1.62bn
- Enterprise value
- $1.03bn
- P/E
- –
- P/S
- –
- P/B
- 7.62
- EV/Sales
- –
- EV/EBITDA
- –
- Earnings yield
- –
- FCF yield
- -15.0%
Results (last four quarters)
- Revenue
- –
- Gross profit
- –
- EBITDA
- −$526m
- Net income
- −$542m
- Earnings per share
- −$10.05
- Revenue per share
- –
- Revenue growth
- –
- Earnings growth
- –
Profitability
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity
- -265.1%
- Return on assets
- -80.2%
Balance sheet and cash flow
- Cash
- $585m
- Cash per share
- $8.63
- Financial debt
- –
- Debt/equity %
- –
- Current ratio
- 9.42
- Book value per share
- $3.13
- Operating cash flow
- −$243m
- Free cash flow
- −$243m
Dividend
- Dividend yield
- 0.00%
- Dividend (12 months)
- $0.00
- Yield (12 months)
- 0.00%
- Payout ratio
- –
- Ex-dividend date
- –
Shares and trading
- Shares outstanding
- 67.8m
- Volume
- 576,521
- Avg. volume 3 months
- 647,934
- Relative volume
- 1.0
Price and technicals
- Price
- $23.85
- 1 day
- −4.8%
- 52-week high
- $43.17
- 52-week low
- $15.20
- Distance to 52-week high
- −44.8%
- Distance to 52-week low
- +56.9%
- Distance to 50-day line
- −14.8%
- Distance to 200-day line
- −6.5%
- RSI (14)
- 33
- Volatility 1M
- 62.7%
Performance
- 1 week
- −14.9%
- 1 month
- −15.5%
- 3 months
- −24.6%
- 6 months
- +25.7%
- YTD
- −34.3%
- 1 year
- −35.8%
Dates
- Fiscal year end
- 31 Dec 2025
- Most recent quarter
- 30 Sep 2026
Frequently asked questions
How has ZBIO performed since 09/2024?
$10,000 grew to $13,140 by 20 Nov 2026, which is +13.3% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.
How volatile is ZBIO?
Volatility was 100.1% per year, measured on monthly returns. The largest decline from a peak was −75.0%, with the low in 01/2025.
How does ZBIO compare with a broad equity ETF?
Over the same period Global equities (VT) returned +11.4% per year at 13.2% volatility, ZBIO returned +13.3% at 100.1%. The correlation of monthly returns was 0.02; 1 would mean they moved in lockstep.
Which currency are the figures in?
In US dollars, the currency of the US listing.